在进一步研究之前,林业发展局批准稀有自闭症相关条件的Leucovorin。 FDA approves leucovorin for rare autism-linked condition, pending further research.

根据有限的临床证据，FDA 已批准亚叶酸（叶酸的一种形式）用于治疗脑叶酸缺乏症，这是一种与自闭症样症状相关的罕见疾病。 The FDA has approved leucovorin, a form of folate, for treating cerebral folate deficiency, a rare condition linked to autism-like symptoms, based on limited clinical evidence. 虽然它不是自闭症谱系障碍的治疗方法,但早期研究表明,白素可能会改善某些具有特定生物标记的儿童的沟通,社交技能和行为,例如叶酸受体自身抗体或影响叶酸处理的遗传问题. While not a cure for autism spectrum disorder, early studies suggest leucovorin may improve communication, social skills, and behavior in some children with specific biological markers such as folate receptor autoantibodies or genetic issues affecting folate processing. 这种药物已经用于贫血和化疗副作用,现正在研究这种药物,但自闭症不在标签之列,但专家告诫说,在小型试验中,证据仍然有限,而且不一致。 The drug, already used for anemia and chemotherapy side effects, is being explored off-label for autism, but experts caution that evidence remains limited and inconsistent across small trials. GlaxoSmithKline(GlaxoSmithKline)于2025年9月22日宣布予以批准,这反映出人们对针对神经发育状况的定向治疗越来越感兴趣,尽管需要进行更大规模的长期研究,以确认安全和有效性。 The approval, made by GlaxoSmithKline and announced on September 22, 2025, reflects growing interest in targeted treatments for neurodevelopmental conditions, though larger, long-term research is needed to confirm safety and effectiveness. 卫生官员强调使用前进行个性化医疗评价的重要性。 Health officials emphasize the importance of individualized medical evaluation before use.